Brief: Sprint Bioscience And Max IV Receive Funding From Vinnova
01/10/2026 09:01
BRIEF-Sprint Bioscience And Max IV Receive Funding From Vinnova Oct 1 (Reuters) - Sprint Bioscience AB SPRINT.ST:
CO AND MAX IV RECEIVE SEK 940,000 FUNDING FROM VINNOVA FOR RESEARCH PROJECT
ELIGIBLE FOR UP TO SEK 704,000 FUNDING FROM NOV 2026 TO OCT 2028
Source text: https://mfn.se/a/sprint-bioscience/sprint-bioscience-erhaller-finansiering-fran-vinnova
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln